Intratubular RISUG
- User: Female
- Hormonal: Non-Hormonal
-
Delivery type:
- Fallopian Tube
-
Intended Duration:
- Permanent
- Long-Acting
- Development Stage: Pre-Clinical
- Developer(s)/researcher(s): Indian Institute of Technology, Kharagpur University of Rajasthan
Details
- API: SMA
-
Mechanism of Action:
- Tubal Occlusion
- Inactive Materials: DMSO
- Regimen: Single Administration
- MPT: Not Potential MPT
- Promising Attributes: RISUG has the potential to offer both male and female patients a non-surgical and reversable option for either permanent or temporary sterilization.
Product Status
Recent Pre-Clinical Evaluation in Female Mice
History
1979: RISUG, a single injection of styrene maleic anhydride dissolved in DMSO, is first tested as a non-surgical, reversible method of male sterilization. The product would be evaluated through animal studies - with varied results - from 1980-1993.
1993-Present: Researchers affiliated with IIT New Delhi publish the results Phase I and Phase II clinical trials, which find that while RISUG does generally produce infertility, further conclusions regarding safety and efficacy cannot be definitively made. Additional Phase III research is planned.
2010: IIT Kharagpur receives a Gates Grand Challenges exploration grant to determine the viability of RISUG as a method for reversible female sterilization.
2021: The University of Rajasthan publishes results from a rat study that documented 0 pregnancies among 60 female rats for 90 days after administration of RISUG in the fallopian tubes and a gradual return to fertility following reversal.
Publications
Additional Information
See record "Vas Deferens RISUG" for use of SMA & DMSO as a male method